VTE prevalence, by FVL status
| . | Full cohort . | European . | Latine . | African . | East Asian . | South Asian . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Noncarriers . | FVL carriers . | Noncarriers . | FVL carriers . | Noncarriers . | FVL carriers . | Noncarriers . | FVL carriers . | Noncarriers . | FVL carriers . | Noncarriers . | FVL carriers . | |
| VTE, n (%) | 81 410 (2.04%) | ≥12 912 (6.93%) | 70 332 (2.33%) | 12113 (7.33%) | 6582 (1.13%) | 647 (3.83%) | 3865 (1.94%) | 140 (4.88%) | 432 (0.27%) | <5∗ | 199 (0.49%) | 12 (1.14%) |
| PE, n (%) | 33 286 (0.83%) | ≥4 565 (2.45%) | 28 552 (0.95%) | 4278 (2.59%) | 2604 (0.45%) | 229 (1.35%) | 1894 (0.95%) | 58 (2.02%) | 159 (0.10%) | <5∗ | 77 (0.19%) | <5∗ |
| Isolated DVT, n (%) | 48 124 (1.21%) | ≥8 346 (4.59%) | 41 780 (1.40%) | 7835 (4.87%) | 3978 (0.69%) | 418 (2.51%) | 1971 (1.00%) | 82 (2.92%) | 273 (0.17%) | <5∗ | 122 (0.30%) | 11 (1.05%) |
| . | Full cohort . | European . | Latine . | African . | East Asian . | South Asian . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Noncarriers . | FVL carriers . | Noncarriers . | FVL carriers . | Noncarriers . | FVL carriers . | Noncarriers . | FVL carriers . | Noncarriers . | FVL carriers . | Noncarriers . | FVL carriers . | |
| VTE, n (%) | 81 410 (2.04%) | ≥12 912 (6.93%) | 70 332 (2.33%) | 12113 (7.33%) | 6582 (1.13%) | 647 (3.83%) | 3865 (1.94%) | 140 (4.88%) | 432 (0.27%) | <5∗ | 199 (0.49%) | 12 (1.14%) |
| PE, n (%) | 33 286 (0.83%) | ≥4 565 (2.45%) | 28 552 (0.95%) | 4278 (2.59%) | 2604 (0.45%) | 229 (1.35%) | 1894 (0.95%) | 58 (2.02%) | 159 (0.10%) | <5∗ | 77 (0.19%) | <5∗ |
| Isolated DVT, n (%) | 48 124 (1.21%) | ≥8 346 (4.59%) | 41 780 (1.40%) | 7835 (4.87%) | 3978 (0.69%) | 418 (2.51%) | 1971 (1.00%) | 82 (2.92%) | 273 (0.17%) | <5∗ | 122 (0.30%) | 11 (1.05%) |
Note that, to respect 23andMe research participant privacy, we are unable to provide specific counts in which n was <5.